cas 1255099-13-8|| where to buy Methyl 3-ethynyl-4-methylbenzoate

製品名:Methyl 3-ethynyl-4-methylbenzoate

IUPAC Name:methyl 3-ethynyl-4-methylbenzoate

包装単位	有効在庫	価格（USD）
CM318788-1g	in stock	ǊŴƦ
CM318788-5g	in stock	ȬƦȁ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1255099-13-8 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:1255099-13-8; 分子式:C11H10O2; 融点:-; SMILESコード:O=C(OC)C1=CC=C(C)C(C#C)=C1; 密度:

: カタログ番号:CM318788; 分子量:174.2; 沸点:; MDL番号:MFCD17926442; 保管方法:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Olverembatinib; Ascentage Pharma announced that updated results from three studies of olverembatinib, have been released in posters at the 2024 European Hematology Association Hybrid Congress, taking place in Madrid, Spain.
Olverembatinib (HQP1351) is an oral, third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) developed by Ascentage Pharma for the treatment of chronic myeloid leukaemia (CML), acute myeloid leukaemia, acute lymphoblastic leukaemia (ALL) and solid tumours, including gastrointestinal stromal tumours (GIST). Olverembatinib is an ATP binding-site inhibitor of wild type BCR-ABL1 kinase and a broad spectrum of BCR-ABL1 mutants, including mutant T315I, which confers resistance against all first- and second-generation TKIs.